ORTHOPEDIATRICS CORP

KIDS

Held by 2 specialist biotech funds

Share on X

Fund Holdings

RA Capital Management Deerfield Management

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

RA Capital ManagementNEWFeb 17, 2026

Shares: 109,959Value: $2.0M

# Signal Note: RA Capital Initiates ORTHOPEDIATRICS (KIDS) RA Capital's entry into KIDS suggests conviction in the pediatric orthopedic device market, where the company holds a dominant position in trauma and sports medicine implants with limited competition. The $2.0M position (modest in absolute terms) indicates a measured conviction level, likely reflecting either early-stage pipeline visibility or attractive valuation rather than an imminent catalyst. No major near-term catalysts are publicly evident, suggesting RA is positioning for medium-term margin expansion or M&A activity in the fragmented pediatric orthopedic space.

Deerfield ManagementNEW

More KIDS Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

SION2 funds SPRY2 funds TSHA2 funds INSP2 funds BCRX2 funds NUVL2 funds MNPR2 funds SYRE

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: Deerfield Entry into OrthoPediatrics (KIDS) Deerfield's $2.6M initiation in KIDS suggests conviction in the pediatric orthopedic device company's growth trajectory, likely tied to its flagship products (lateral-entry intramedullary nailing systems, growth-guidance systems) gaining market share in a fragmented $2.8B+ pediatric ortho market. The timing may reflect confidence in recent FDA clearances, reimbursement expansion, or upcoming surgical volume recovery post-pandemic. As a healthcare multi-strategy fund, Deerfield's entry is notable but modest in absolute terms—worth monitoring for institutional validation rather than as a major inflection point.